Aging Clinical Trial
Official title:
Effects of Dancing and Walking on Cardiovascular Risk Factors and Functional Capacity in Older Women: a Randomized Controlled Trial.
The goal of this randomized controlled trial is to investigate the effects of a dance intervention on cardiovascular risk factors and functional capacity of older women, comparing dancing to a walking exercise intervention and to an active control condition (stretching). The participants will include women between 60 and 80 years old, with body mass index inferior to 35 Kg /m2. The main outcome of this study is the peak oxygen consumption (VO2peak). The secondary outcomes are cardiovascular risk associated factors (C-reactive protein, TNF-alpha, lipid profile, etc) and functional performance (muscle strength and power, balance, gate ability, etc). The experimental design will include 3 parts: 1) Pre-intervention assessments: medical evaluation, fasting blood exams, maximum exercise test, assessments of body composition, balance, gate ability, muscular strength and power. 2) Period of interventions: patients will be randomized to one of the three following groups: dance, walking or stretching. The duration of the interventions will be 8 weeks, including 3 sessions per week for dance and walking, and once a week for the stretching group. Each session will last 60 min. 3) Post-intervention assessments: the same protocols of testing as pre-intervention.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | August 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 60 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Women between 60 and 80 years old - BMI inferior to 35 kg/m2 - Independent for performing daily activities (OARS scale) - Not engaged in any type of regular exercise programme for the past 6 months Exclusion Criteria: - Type 2 diabetes mellitus, dyslipidemia, cardiovascular diseases or other non-controlled metabolic disorders - Chronic diseases such as fibromyalgia, cancer or neurodegenerative disorders - Bone, joints or muscle problems that could impair exercise performance - Not being able to perform the effort test in the first assessment session, abnormal electrocardiogram, or any other condition identified by the physician of the study that limit the engagement in an exercise training programme. |
Country | Name | City | State |
---|---|---|---|
Brazil | Universidade Federal do Rio Grande do Sul | Porto Alegre | Rio Grande do Sul |
Lead Sponsor | Collaborator |
---|---|
Federal University of Rio Grande do Sul |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Peak Oxygen Consumption (VO2peak) | The maximum capacity of oxygen consumption measured during an incremental exercise test. | Baseline and 8 weeks | |
Secondary | Change in C-reactive protein (CRP) | Cardiovascular risk marker. It will be analyzed in plasma, using ELISA specific kits. | Baseline and 8 weeks | |
Secondary | Change in Tumor necrosis factor alpha (TNF-alpha) | Inflammatory marker. It will be analyzed in plasma, using ELISA specific kits. | Baseline and 8 weeks | |
Secondary | Change in Triglycerides | Lipid profile marker. It will be analyzed in plasma, by enzymatic colorimetric method, using an automatic analyzer (ROCHE, Cobas C111, Switzerland). | Baseline and 8 weeks | |
Secondary | Change in Total Cholesterol | Lipid profile marker. It will be analyzed in plasma, by enzymatic colorimetric method, using an automatic analyzer (ROCHE, Cobas C111, Switzerland). | Baseline and 8 weeks | |
Secondary | Change in LDL-Cholesterol | Lipid profile marker. Estimation of the LDL concentration will be calculate using the formula of Friedewald. | Baseline and 8 weeks | |
Secondary | Change in HDL-Cholesterol | Lipid profile marker. It will be analyzed in plasma, by enzymatic colorimetric method, using an automatic analyzer (ROCHE, Cobas C111, Switzerland). | Baseline and 8 weeks | |
Secondary | Change in Fasting Glycemia | Glycaemic profile marker. It will be analyzed in plasma, by enzymatic colorimetric method, using an automatic analyzer (ROCHE, Cobas C111, Switzerland). | Baseline and 8 weeks | |
Secondary | Change in Fasting Insulin | Glycaemic profile marker. It will be measured in plasma, usin a high sensitivity enzyme-linked immunosorbent assay. | Baseline and 8 weeks | |
Secondary | Change in HOMA-IR | Glycaemic profile marker. Homeostatic model of insulin resistance. It will be calculated according to the following formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. | Baseline and 8 weeks | |
Secondary | Change in Muscle Strength | Isometric peak torque of the knee extensors will be measured using an isokinetic dynamometer (Cybex Norm, EUA). | Baseline and 8 weeks | |
Secondary | Change in Muscle Power | Lower body muscle power will be measured by the performance of the counter movement jump in a force platform. | Baseline and 8 weeks | |
Secondary | Change in Muscle Quality | Echo intensity of the quadriceps will be analyzed by ultrasound images. | Baseline and 8 weeks | |
Secondary | Change in Static Balance | Static balance will be measured by a single leg support balance test, performed with both legs, with the eyes open and closed. | Baseline and 8 weeks | |
Secondary | Change in Dynamic Balance | Dynamic balance will be measured by the Time to Up ang Go (TUG) test. | Baseline and 8 weeks | |
Secondary | Change in Gate ability | Gate ability will be measured in a 10m track, picking up objects and passing over obstacles. | Baseline and 8 weeks | |
Secondary | Change in Body Weight | Measurements of body weight will be measured in a digital scale. | Baseline and 8 weeks | |
Secondary | Change in Waist Circumference | Measurements of waist circumference will be performed with a measuring tape. | Baseline and 8 weeks | |
Secondary | Change in Percentage of Body Fat | Measurements of skinfolds will be taken to calculate the percentage of body fat. | Baseline and 8 weeks | |
Secondary | Change in Sit and Stand ability | The ability to sit and stand in a chair 5 times, as fast as possible. | Baseline and 8 weeks | |
Secondary | Changes in Fall Risk | The risk of fall will be measured by the performance in the TUG test. | Baseline and 8 weeks | |
Secondary | Changes in the Fear of Falling | The fear of falling will be analyzed by the Falls Efficacy Scale-International Brazil (FES-I-Brazil). | Baseline and 8 weeks | |
Secondary | Changes in Quality of Life | Quality of life will be analyzed by the questionary WHOQOL (World Health Organization Quality of Life. | Baseline and 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Completed |
NCT05293730 -
Trial of the Impact of the Electronic Frailty Integrated With Social Needs
|
N/A | |
Recruiting |
NCT03932162 -
Gene Expression Changes In Young and Geriatric Skin
|
Early Phase 1 | |
Completed |
NCT04064528 -
Effects of Age on Amino Acid Delivery to Tendon
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT06029920 -
Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT05566938 -
Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly
|
N/A | |
Recruiting |
NCT05543980 -
Leg Heat Therapy in Elderly Individuals
|
Phase 2 | |
Completed |
NCT04894929 -
Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement
|
N/A | |
Not yet recruiting |
NCT06071130 -
Emotion, Aging, and Decision Making
|
N/A | |
Enrolling by invitation |
NCT04641663 -
Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST)
|
N/A | |
Completed |
NCT04088006 -
The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity
|
N/A | |
Completed |
NCT03695081 -
Patient Pathway Pharmacist - Optimal Drug-related Care
|
N/A | |
Recruiting |
NCT05424263 -
Acetate and Age-associated Arterial Dysfunction
|
Phase 2 | |
Completed |
NCT05601713 -
Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling
|
N/A | |
Completed |
NCT04551339 -
Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19
|
N/A | |
Recruiting |
NCT04997577 -
Speech Perception and High Cognitive Demand
|
N/A | |
Completed |
NCT05922475 -
Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training
|
N/A | |
Completed |
NCT04015479 -
Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults
|
N/A |